Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
GlaxoSmithKline
Study ID
NCT06790303
Phase
PHASE2
Status
Terminated

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Feladilimab — DRUG
    Feladilimab will be administered.
  • Ipilimumab — DRUG
    Ipilimumab will be administered

Study Details

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.

Key Dates

Start date
Mar 4, 2021
Status verified
May 2025
Primary completion
Sep 23, 2021
Completion
Sep 23, 2021

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Feladilimab plus Ipilimumab

Primary Outcome Measure

Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 29 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteNashvilleTennessee37203-

Find similar trials in Nashville, TN

By research site
GSK Investigational Site· Nashville, TN

Related Studies